QuiaPEG

Newsroom

Filter news by year:
Page:
1234
June 30, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today presented further positive results from a preclinical study in the model project QPG-1029 (pegylated liraglutide), for the treatment of type 2 diabetes and overweight. The study results are necessary for modeling dose and dose ranges in upcoming multiple dose studies. The study was performed after optimizing the synthesis method of QPG-1029 and evaluated the pharmacokinetic properties after subcutaneous administration in the rat.

May 24, 2020

The shareholders of QuiaPEG Pharmaceuticals Holding AB, company reg. no 556658-0196, are hereby given notice to attend the Annual General Meeting to be held on June 22, 2020 at 2.00 pm at MAQS Advokatbyrå, Hamngatan 13 in Stockholm. Registration to the Annual General Meeting begins at 1.30 pm.

May 18, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved versions of clinically validated or already approved drugs, today announced it signed an agreement with the Chinese pharmaceutical company Chengdu Shengnuo Biopharm Co.,Ltd (”SNBio”), which pays $200,000 (approx. 2 MSEK) in exchange for being able to evaluate for a limited time a proprietary drug together with one of QuiaPEG's releasable activated PEGs from the technology platform Uni-Qleaver®.

May 06, 2020

The Board of Directors of QuiaPEG Pharmaceuticals Holding AB (publ) (the "Company") has decided to postpone the Annual General Meeting, which was originally planned to be held on June 11, 2020. The new date for the Annual General Meeting is June 22, 2020. The postponement is made with regard to current uncertainties as a result of the Covid-19 pandemic. The Company considers that a postponement improves the Company's ability to conduct the Annual General Meeting in a satisfactory manner. Notice of the Annual General Meeting and publication of the Company's annual report will be published in the usual way, taking into account the provisions of the Companies Act and the Articles of Association. Thus, the annual report will be published no later than June 8, 2020.

Apr 07, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today announced it has signed an agreement with the German company Celares GmbH to develop an optimized process suitable for large scale production of products based onQuiaPEG’sUni-Qleaver technology, including QPG-1029 according to current Good Manufacturing Practice (cGMP).

Feb 25, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today demonstrated Proof-of-Concept after positive results from a preclinical efficacy study in the QPG-1029 research project (pegylated liraglutide), for the treatment of type 2 diabetes and obesity.

Feb 11, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today presented positive results from a preclinical study in the research project QPG-1029 (pegylated liraglutide), for the treatment of type 2 diabetes and overweight. The study evaluated the pharmacokinetic properties of QPG-1029 after intravenous and subcutaneous administration in rats.

Feb 06, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, today announces that the company, in collaboration with a reputable global contract research company, has developed bioanalytical methods for the drug candidate QPG-1029 (PEG liraglutide) and the active drug substance liraglutide.

Jan 28, 2020

In accordance with a decision at the Annual General Meeting on May 29, 2019 in QuiaPEG Pharmaceuticals Holding AB, the three members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed by the Company's two largest shareholders, according to voting rights, as of September 30, 2019, each entitled to nominate one member of the Nomination Committee. As the company's holders of the most shares declined to appoint a member to the nomination committee, Marcus Bosson, as the third largest shareholder, may therefore appoint a member. In addition, the Nomination Committee shall consist of one member appointed by the Board of Directors.

Jan 28, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG") has previously announced that the company's annual report for the period January-December 2019 will be published on March 6th, 2020. The Board of Directors of QuiaPEG has now decided to bring forward the date for publication of the interim report to February 28th, 2020.

Page:
1234
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message